Catalyst
Slingshot members are tracking this event:
Ionis Pharma (IONS) to complete Phase 3 study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients with Familial Chylomicronemia Syndrome in March 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IONS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 06, 2017
Occurred Source:
http://ir.ionispharma.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2251615
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Study, Volanesorsen, Ionis-apociiirx, Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia
